Evaluation of methods for estimating time to steady state with examples from phase 1 studies

AAPS Journal

Volumn 10, Issue 1, 2008, Pages 141-147

  Maganti, Lata ^a   Panebianco, Deborah L ^a   Maes, Andrea L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Effective half life; Helmert contrasts; No statistical significance of trend; Nonlinear mixed effect modeling; Steady state

Indexed keywords

AREA UNDER THE CURVE; BAYES THEOREM; DRUG ACCUMULATION; DRUG HALF LIFE; DRUG RESEARCH; HUMAN; MONTE CARLO METHOD; NONLINEAR SYSTEM; PROBABILITY; REVIEW; STATISTICAL SIGNIFICANCE; STEADY STATE;

ANIMALS; AREA UNDER CURVE; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; PHARMACEUTICAL PREPARATIONS; STATISTICS AS TOPIC; TIME;

EID: 51249104233     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-008-9014-y     Document Type: Review

References (12)

1. W. W. Hauck, N. T. Tozer, S. Anderson, and Y. F. Bois. Considerations in the attainment of steady state: Aggregate vs. individual assessment. Pharm. Res. 15(11):1796-1798 (1998).
2. W. L. Chiou. Rapid compartment-and model-independent estimation of times required to attain various fractions of steady-state plasma level during multiple dosing of drugs obeying superposition principle and having various absorption or infusion kinetics. J. Pharm. Sci. 68(12):1546-1547 (1979).
3. D. Perrier, and M. Gibaldi. General derivation of the equation for time to reach a certain fraction of steady state. J. Pharm. Sci. 71(4):474-475 (1982).
4. K. C. Kwan, N. R. Bohidar, and S. S. Hwang. Chapter 14: Estimation of an effective half-life. In Proceedings of the Sidney Riegelman Memorial Symposium held April 22-24, 1982 at the University of California, San Francisco, California. Plenum, New York, 1984, pp. 147-162.
5. J. W. Tukey, J. L. Ciminera, and J. F. Heyse. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics. 41:295-301 (1985).
6. R. Marcus, E. Peritz, and K. R. Gabriel. On closed testing procedures with special reference to ordered analysis of variance. Biometrica. 63:655-660 (1976).
7. Chow SC and Liu JP. Chapter 12: Some related problems in bioavailability studies. In: Design and analysis of bioavailability and bioequivalence studies. Marcel Dekker, New York, 1992.
8. D. Hoffman, R. Kringle, G. Lockwood, S. Turpault, E. Yow, and G. Mathiew. Nonlinear mixed effects modeling for estimation of steady state attainment. Pharm. Stat. 4: 15-24 (2005).
9. L. Maganti and D. Panebianco. Assessment of time to steady state: nonlinear mixed effect modeling versus traditional methods. ASCPT, Anaheim, March 21-24, 2007.
10. P. Jordan, H. Brunschwig, and E. Luedin. Modeling attainment of steady state of drug concentration in plasma by means of a Bayesian approach using MCMC methods. Pharm Stat. (in press) (2007). www.interscience.wiley.com. DOI 10.1002/pst.263. Accessed May 7, 2007.
11. SAS online documentation, SAS/STAT Users Guide, Version 8, SAS Institute, Cary, NC (2005).
12. WinBUGS software [Computer program]. Version 1.4.2, MRC Biostatistics Unit, Cambridge, UK, March 2007